Side-by-side · Research reference

CagrilintidevsTeriparatide

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 3HUMAN-REVIEWED35/64 cited

BFDA-ApprovedHUMAN-REVIEWED10/62 cited

Cagrilintide

Long-Acting Amylin Analogue · Phase 3

7.5%Additional weight loss vs semaglutideAhmed 2026

Once weeklyDosing frequencyBailey 2026

Dual AMYR/CTRReceptor agonismBailey 2026

SQ · Once WeeklyBailey 2026

Teriparatide

PTH (1-34) Fragment · FDA-Approved

20 mcgDaily dose

12-18 moAnabolic windowFerrari 2026

SQRoute

SQ · Thigh/Abdomen · Once Daily

01Mechanism of Action

Parameter

Cagrilintide

Teriparatide

Primary target

Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026

Parathyroid hormone 1 receptor (PTH1R) on osteoblastsXue 2026

Pathway

AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026

PTH1R activation → cAMP/PKA signaling → osteoblast differentiation and activity

Downstream effect

Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026 Yamauchi 2026

Stimulates osteoblast formation and bone matrix deposition; increases bone mineral density at trabecular and cortical sites

Feedback intact?

Yes — acts via physiological amylin pathways

Yes — intermittent dosing preserves anabolic effect; continuous exposure causes catabolic bone resorption

Origin

Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026

Recombinant 34-amino-acid N-terminal fragment of 84-amino-acid human PTH

Antibody development

—

02Dosage Protocols

Parameter

Cagrilintide

Teriparatide

Standard dose (combination)

Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026

Phase 3 REDEFINE 5 trial dosing.

—

Monotherapy dosing

Dose-dependent, under investigation

Monotherapy trials reported in meta-analysis.

—

Frequency

Once weekly (subcutaneous)Bailey 2026

Long-acting formulation.

Once daily

Intermittent administration preserves anabolic effect.

Evidence basis

Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026 Ahmed 2026

RCT / FDA-approved

Duration

26–52 weeks in trialsYamauchi 2026

—

Route

Subcutaneous injectionBailey 2026

Subcutaneous (thigh or abdomen)

Standard dose (osteoporosis)

—

20 mcg / day

FDA-approved regimen for severe osteoporosis.

Maximum duration

—

24 months lifetime

Anabolic effect wanes after 12-18 months; FDA recommends max 2-year cumulative exposure.

Hypoparathyroidism dose

—

20 mcg / day

Used off-label for chronic hypoparathyroidism.

Pelvic fragility fractures

—

20 mcg / day × 8-12 weeks

Accelerates fracture healing; reduces time to union.Crooks 2026

Timing

—

Morning or evening (flexible)

Storage

—

Refrigerate 2-8 °C; pen device stable at room temp for 28 days after first use

Pharmacogenetics

—

ALDH2 polymorphisms may influence BMD responseObara 2026

ALDH2*2 variant carriers show altered PTH receptor expression.Obara 2026

03Metabolic / Fat Loss Evidence

Parameter

Cagrilintide

Teriparatide

Weight loss vs semaglutide

7.47% greater percentage weight lossAhmed 2026

CagriSema combination vs semaglutide monotherapy (meta-analysis).

—

Absolute weight change

Significantly greater absolute weight reductionAhmed 2026

Mean difference favoring combination therapy.

—

Mechanism

Central satiety inductionBailey 2026

—

BMI reduction

Significant BMI reduction vs comparatorAhmed 2026

—

Glycemic benefit

Reduced fasting glucose and HbA1cAhmed 2026

Synergistic effect with semaglutide in combination.

—

Lipid effects

Improvements in total cholesterol, LDL-C, HDL-C, VLDL-C, triglyceridesAhmed 2026

—

Body composition

Predominant fat loss with weight reduction

—

Mitochondrial function

In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026

C2C12 myotube study; clinical relevance under investigation.

—

Combination rationale

Multi-pathway approach: amylin (satiety) + GLP-1 (incretin)Lempesis 2026

—

Key publications

REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026 Ahmed 2026 Bailey 2026

—

Fat loss application

—

None — teriparatide is a bone anabolic agent without direct lipolytic activity

04Side Effects & Safety

Parameter

Cagrilintide

Teriparatide

Gastrointestinal

Nausea, diarrhea (common with incretin-based therapies)Pardali 2026

Dietary management and nutritional monitoring recommended.

—

Injection site reactions

Local reactions possible with subcutaneous administration

—

Safety profile

Generally consistent with incretin-based therapies

Phase 3 and meta-analysis safety data.

—

Tolerability

Tolerability considerations similar to GLP-1RAs

—

Muscle preservation

Lean mass considerations during weight loss

In vitro mitochondrial effects observed; clinical impact under investigation.

—

Hypercalcemia

—

Transient serum calcium elevation 4-6 hours post-injection

Monitor serum calcium; usually asymptomatic.

Orthostatic hypotension

—

Dizziness, lightheadedness within hours of injection

Nausea

—

Common, usually mild and transient

Leg cramps / Arthralgia

—

Musculoskeletal pain reported in clinical trials

Hypercalciuria

—

Increased urinary calcium excretion; monitor for nephrolithiasis risk

Osteosarcoma (black box warning)

—

Rat studies showed dose-dependent osteosarcoma; not observed in humans to date; contraindicated in Paget's disease, skeletal malignancy, prior radiation

Injection site reaction

—

Erythema, bruising, pain (uncommon)

Absolute Contraindications

Cagrilintide

·Hypersensitivity to cagrilintide or formulation components

Teriparatide

·Paget's disease of bone (increased baseline osteosarcoma risk)
·Unexplained elevated alkaline phosphatase
·Prior skeletal radiation therapy
·Skeletal malignancies or bone metastases
·Hypercalcemic disorders (primary hyperparathyroidism)
·Pregnancy / lactation

Relative Contraindications

Cagrilintide

·Severe gastrointestinal disease
·History of pancreatitis (incretin-based therapy consideration)

Teriparatide

·Active or recent nephrolithiasis
·Severe renal impairment (CKD G4-G5)
·Hypercalciuria without adequate monitoring

05Administration Protocol

Parameter

Cagrilintide

Teriparatide

1. Dosing frequency

Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026

Teriparatide is supplied in pre-filled pen injectors (Forteo pen). Store refrigerated at 2-8 °C until first use. After first injection, pen may be kept at room temperature for up to 28 days. Do not freeze.

2. Combination form

Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026 Bailey 2026

Subcutaneous injection into thigh or lower abdomen. Rotate sites daily to avoid lipodystrophy. Avoid areas with scars, bruises, or active skin conditions.

3. Injection site

Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.

Once daily, at approximately the same time each day. Morning or evening administration is acceptable. Take while sitting or lying down to minimize orthostatic hypotension risk.

4. Storage

Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.

Clean injection site with alcohol swab. Pinch skin, insert needle at 90° angle, and inject full dose (20 mcg). Hold for 5 seconds before withdrawing needle. Do not rub injection site.

5. Dietary considerations

Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026

Baseline and periodic monitoring of serum calcium, urinary calcium, serum PTH (if hypoparathyroidism), and bone mineral density (DXA scan). Monitor for hypercalcemia 4-6 hours post-dose if symptomatic.

6. Calcium and vitamin D supplementation

—

Ensure adequate calcium (1000-1200 mg/day) and vitamin D (800-1000 IU/day) intake unless contraindicated by hypercalcemia or hypercalciuria.

06Stack Synergy

Cagrilintide

+ Semaglutide

Strong

View Semaglutide →

Cagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.

CagriSema: Cagrilintide 2.4 mg + Semaglutide 2.4 mg
Frequency: Once weekly subcutaneous
Duration: 26–52 weeks (trial data)
Primary benefit: Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation

Yamauchi 2026 Ahmed 2026 Bailey 2026

Teriparatide

— no documented stacks